JS-K, a glutathione/glutathione S-transferase-activated nitric oxide releasing prodrug inhibits androgen receptor and WNT-signaling in prostate cancer cells

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Laschak, Martin ^a   Spindler, Klaus Dieter ^a   Schrader, Andres J ^a   Hessenauer, Andrea ^a   Streicher, Wolfgang ^a   Schrader, Mark ^a   Cronauer, Marcus V ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 3 NITROTYROSINE; 3,3 BIS(2 AMINOETHYL) 1 HYDROXY 2 OXOTRIAZENE; ANDROGEN RECEPTOR; BETA CATENIN; GLUTATHIONE; GLUTATHIONE TRANSFERASE; GREEN FLUORESCENT PROTEIN; HYBRID PROTEIN; NITRATE; NITRIC OXIDE; NITRIC OXIDE DONOR; O2 (2,4 DINITROPHENYL) 1 [(4 ETHOXYCARBONYL)PIPERAZIN 1 YL]DIAZEN 1 IUM 1,2 DIOLATE; PRODRUG; UNCLASSIFIED DRUG; WNT PROTEIN; ANTINEOPLASTIC AGENT; AZO COMPOUND; O(2) (2,4 DINITROPHENYL) 1 ((4 ETHOXYCARBONYL)PIPERAZIN 1 YL)DIAZEN 1 IUM 1,2 DIOLATE; O(2)-(2,4-DINITROPHENYL) 1-((4-ETHOXYCARBONYL)PIPERAZIN-1-YL)DIAZEN-1-IUM-1,2-DIOLATE; PIPERAZINE DERIVATIVE;

AMINO ACID ANALYSIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CASTRATION RESISTANT PROSTATE CANCER; CELL LEVEL; CELL PROLIFERATION; CELL STRAIN LNCAP; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; CYTOPLASM; DIMERIZATION; DOWN REGULATION; DRUG EFFECT; DRUG IDENTIFICATION; DRUG MECHANISM; ENZYME ACTIVATION; FLUORESCENCE MICROSCOPY; GENE ACTIVITY; HUMAN; HUMAN CELL; IMMUNODETECTION; INTRACELLULAR SIGNALING; INTRACELLULAR TRANSPORT; MALE; NITROSATION; NUCLEAR IMPORT; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; REPORTER GENE; TISSUE CULTURE; TWO HYBRID SYSTEM; WESTERN BLOTTING; WNT SIGNALING PATHWAY; BIOSYNTHESIS; IMMUNOHISTOCHEMISTRY; METABOLISM; PHYSIOLOGY; PROSTATE TUMOR; TUMOR CELL CULTURE;

ANTINEOPLASTIC AGENTS; AZO COMPOUNDS; BLOTTING, WESTERN; CELL PROLIFERATION; GLUTATHIONE TRANSFERASE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NITRIC OXIDE; NITRIC OXIDE DONORS; PIPERAZINES; PRODRUGS; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TUMOR CELLS, CULTURED; WNT SIGNALING PATHWAY;

EID: 84859054218     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-130     Document Type: Article

References (53)

1. Burgaud JL, Riffaud JP, Del Soldato P. Nitric-oxide releasing molecules: A new class of drugs with several major indications. Curr Pharm Design 2002, 8:201-213.
2. Pavlos CM, Xu H, Toscano JP. Photosensitive precursors to nitric oxide. Curr Top Med Chem 2005, 5:637-647. 10.2174/1568026054679326, 16101425.
3. Kanwar JR, Kanwar RK, Burrow H, Baratchi S. Recent advances on the roles of NO in cancer and chronic inflammatory disorders. Curr Med Chem 2009, 16:2373-2394. 10.2174/092986709788682155, 19601787.
4. Ahmad R, Rasheed Z, Ahsan H. Biochemical and cellular toxicology of peroxynitrite: implications in cell death and autoimmune phenomenon. Immunopharmacol Immunotoxicol 2009, 31:388-396. 10.1080/08923970802709197, 19555204.
5. Kiziltepe T, Anderson KC, Kutok JL, Jia L, Boucher KM, Saavedra JE, Keefer LK, Shami PJ. JS-K has potent anti-angiogenic activity in vitro and inhibits tumour angiogenesis in a multiple myeloma model in vivo. J Pharm Pharmacol 2010, 62:145-151. 2925308, 20723011.
6. McMurtry V, Saavedra JE, Nieves-Alicea R, Simeone AM, Keefer LK, Tari AM. JS-K, a nitric oxide-releasing prodrug, induces breast cancer cell death while sparing normal mammary epithelial cells. Int J Oncol 2011, 38:963-971.
7. Cantuaria G, Magalhaes A, Angioli R, Mendez L, Mirhashemi R, Wang J, Wang P, Penalver M, Averette H, Braunschweiger P. Antitumor activity of a novel glyco-nitric oxide conjugate in ovarian carcinoma. Cancer 2000, 88:381-388. 10.1002/(SICI)1097-0142(20000115)88:2<381::AID-CNCR20>3.0.CO;2-M, 10640972.
8. Stevens EV, Carpenter AW, Shin JH, Liu J, Der CJ, Schoenfisch MH. Nitric oxide-releasing silica nanoparticle inhibition of ovarian cancer cell growth. Mol Pharm 2010, 7:775-785. 10.1021/mp9002865, 20205473.
9. Sugita H, Kaneki M, Furuhashi S, Hirota M, Takamori H, Baba H. Nitric oxide inhibits the proliferation and invasion of pancreatic cancer cells through degradation of insulin receptor substrate-1 protein. Mol Cancer Res 2010, 8:1152-1163. 10.1158/1541-7786.MCR-09-0472, 20663861.
10. Royle JS, Ross JA, Ansell I, Bollina P, Tulloch DN, Habib FK. Nitric oxide donating nonsteroidal anti-inflammatory drugs induce apoptosis in human prostate cancer cell systems and human prostatic stroma via caspase-3. J Urol 2004, 172:338-344. 10.1097/01.ju.0000132367.02834.41, 15201807.
11. Huguenin S, Fleury-Feith J, Kheuang L, Jaurand MC, Bolla M, Riffaud JP, Chopin DK, Vacherot F. Nitrosulindac (NCX 1102): a new nitric oxide-donating non-steroidal anti-inflammatory drug (NO-NSAID), inhibits proliferation and induces apoptosis in human prostatic epithelial cell lines. Prostate 2004, 61:132-141. 10.1002/pros.20081, 15305336.
12. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics. CA Cancer J Clin 2010, 60:277-300. 10.3322/caac.20073, 20610543.
13. Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract 2011, 65:1180-1192. 10.1111/j.1742-1241.2011.02799.x, 21995694.
14. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinänen R, Palmberg C, Palotie A, Tammela T, Isola J, Kallioniemi OP. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995, 9:401-406. 10.1038/ng0495-401, 7795646.
15. Hobisch Z, Culig C, Radmayr G, Bartsch H, Klocker A, Hittmair A. Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res 1995, 55:3068-3072.
16. Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H, Hittmair A. Androgen receptor status of lymph node metastases from prostate cancer. Prostate 1996, 28:129-135. 10.1002/(SICI)1097-0045(199602)28:2<129::AID-PROS9>3.0.CO;2-B, 8604394.
17. Cronauer MV, Schulz WA, Burchardt T, Anastasiadis AG, de la Taille A, Ackermann R, Burchardt M. The androgen receptor in hormone-refractory prostate cancer: relevance of different mechanisms of androgen receptor signaling (Review). Int J Oncol 2003, 23:1095-1102.
18. Céraline J, Cruchant MD, Erdmann E, Erbs P, Kurtz JE, Duclos B, Jacqmin D, Chopin D, Bergerat JP. Constitutive activation of the androgen receptor by a point mutation in the hinge region: A new mechanism for androgen-independent growth in prostate cancer. Int J Cancer 2004, 108:152-157. 10.1002/ijc.11404, 14618630.
19. Libertini SJ, Tepper CG, Rodriguez V, Asmuth DM, Kung HJ, Mudryj M. Evidence for calpain-mediated androgen receptor cleavage as a mechanism for androgen independence. Cancer Res 2007, 67:9001-9005. 10.1158/0008-5472.CAN-07-1072, 17909000.
20. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 2008, 68:5469-5477. 10.1158/0008-5472.CAN-08-0594, 2663383, 18593950.
21. Dehm SM, Tindall DJ. Alternatively spliced androgen receptor variants. Endocr Relat Cancer 2011, 18:R183-R196. 10.1530/ERC-11-0141, 21778211.
22. Cronauer MV, Ince Y, Engers R, Rinnab L, Weidemann W, Suschek CV, Burchardt M, Kleinert H, Wiedenmann J, Sies H, Ackermann R, Kröncke KD. Nitric oxide-mediated inhibition of androgen receptor activity: possible implications for prostate cancer progression. Oncogene 2007, 26:1875-1884. 10.1038/sj.onc.1209984, 16983333.
23. Shami PJ, Saavedra JE, Wang LY, Bonifant CL, Diwan BA, Singh SV, Gu Y, Fox SD, Buzard GS, Citro ML, Waterhouse DJ, Davies KM, Ji X, Keefer LK. JS-K, a glutathione/glutathione S-transferase-activated nitric oxide donor of the diazeniumdiolate class with potent antineoplastic activity. Mol Cancer Ther 2003, 2:409-417.
24. Kiziltepe T, Hideshima T, Ishitsuka K, Ocio EM, Raje N, Catley L, Li CQ, Trudel LJ, Yasui H, Vallet S, Kutok JL, Chauhan D, Mitsiades CS, Saavedra JE, Wogan GN, Keefer LK, Shami PJ, Anderson KC. JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells. Blood 2007, 110:709-718. 10.1182/blood-2006-10-052845, 1924477, 17384201.
25. Chen MW, Vacherot F, De La Taille A, Gil-Diez-De-Medina S, Shen R, Friedman RA, Burchardt M, Chopin DK, Buttyan R. The emergence of protocadherin-PC expression during the acquisition of apoptosis-resistance by prostate cancer cells. Oncogene 2002, 21:7861-7871. 10.1038/sj.onc.1205991, 12420223.
26. Schütz SV, Schrader AJ, Zengerling F, Genze F, Cronauer MV, Schrader M. Inhibition of glycogen synthase kinase-3β counteracts ligand-independent activity of the androgen receptor in castration resistant prostate cancer. PLoS One 2011, 6:e25341. 10.1371/journal.pone.0025341, 3183056, 21980429.
27. Cronauer MV, Schulz WA, Ackermann R, Burchardt M. Effects of WNT/β-catenin pathway activation on signaling through T-cell factor and androgen receptor in prostate cancer cell lines. Int J Oncology 2005, 26:1033-1040.
28. Laschak M, Bechtel M, Spindler KD, Hessenauer A. Inability of NCoR/SMRT to repress androgen receptor transcriptional activity in prostate cancer cell lines. Int J Mol Med 2011, 28:645-651.
29. Rinnab L, Schütz SV, Jeannine Diesch J, Schmid E, Küfer R, Hautmann RE, Spindler K-D, Cronauer MV. Inhibiton of Glycogen-Synthase Kinase-3 (GSK) in Androgen Responsive Prostate Cancer Cell Lines - Are GSK-Inhibitors Therapeutically Useful?. Neoplasia 2008, 10:624-634. 2386547, 18516299.
30. Schneider CC, Hessenauer A, Montenarh M, Götz C. p53 is dispensable for the induction of apoptosis after inhibition of protein konase CK2. Prostate 2010, 70:126-134.
31. Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR. Analysis of nitrate, nitrite, and [15 N]nitrate in biological fluids. Anal Biochem 1982, 126:131-138. 10.1016/0003-2697(82)90118-X, 7181105.
32. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983, 65:55-63. 10.1016/0022-1759(83)90303-4, 6606682.
33. Park JG, Kramer BS, Steinberg SM, Carmichael J, Collins JM, Minna JD, Gazdar AF. Chemosensitivity testing of human colorectal carcinoma cell lines using a tetrazolium-based colorimetric assay. Cancer Res 1987, 47:5875-5879.
34. Mazur W, Gonciarz M, Kajdy M, Mazurek U, Jurzak M, Wilczok T, Gonciarz Z. Blood serum glutathione alpha s-transferase (alpha GST) activity during antiviral therapy in patients with chronic hepatitis C. Med Sci Monit 2003, 9(Suppl 3):44-48.
35. Habdous M, Vincent-Viry M, Visvikis S, Siest G. Rapid spectrophotometric method for serum glutathione S-transferases activity. Clin Chim Acta 2002, 326:131-142. 10.1016/S0009-8981(02)00329-7, 12417104.
36. Kröncke KD, Carlberg C. Inactivation of zinc finger transcription factors provides a mechanism for a gene regulatory role of nitric oxide. FASEB J 2000, 14:166-173.
37. Wiedenmann J, Ivanchenko S, Oswald F, Schmitt F, Röcker C, Salih A, Spindler K-D, Nienhaus GU. EosFP, a fluorescent marker protein with UV-inducible green-to-red fluorescence conversion. Proc Natl Acad Sci USA 2004, 101:15905-15910. 10.1073/pnas.0403668101, 528746, 15505211.
38. Tepper CG, Boucher DL, Ryan PE, Ma AH, Xia L, Lee LF, Pretlow TG, Kung HJ. Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Res 2002, 62:6606-6614.
39. Tan J, Sharief Y, Hamil KG, Gregory CW, Zang DY, Sar M, Gumerlock PH, DeVere White RW, Pretlow TG, Harris SE, Wilson EM, Mohler JL, French FS. Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol Endocrinol 1997, 11:450-459. 10.1210/me.11.4.450, 9092797.
40. Wang G, Wang J, Sadar MD. Crosstalk between the androgen receptor and beta-catenin in castrate-resistant prostate cancer. Cancer Res 2008, 68:9918-9927. 10.1158/0008-5472.CAN-08-1718, 2654418, 19047173.
41. Yang X, Chen MW, Terry S, Vacherot F, Bemis DL, Capodice J, Kitajewski J, de la Taille A, Benson MC, Guo Y, Buttyan R. Complex regulation of human androgen receptor expression by Wnt signaling in prostate cancer cells. Oncogene 2006, 25:3436-3444. 10.1038/sj.onc.1209366, 2630384, 16474850.
42. Prévotat L, Filomenko R, Solary E, Jeannin JF, Bettaieb A. Nitric oxide-induced down-regulation of beta-catenin in colon cancer cells by a proteasome-independent specific pathway. Gastroenterology 2006, 131:1142-1152. 10.1053/j.gastro.2006.07.017, 17030184.
43. Nath N, Vassell R, Chattopadhyay M, Kogan M, Kashfi K. Nitro-aspirin inhibits MCF-7 breast cancer cell growth: effects on COX-2 expression and Wnt/beta-catenin/TCF-4 signaling. Biochem Pharmacol 2009, 78:1298-1304. 10.1016/j.bcp.2009.06.104, 19576865.
44. Nath N, Chattopadhyay M, Pospishil L, Cieciura LZ, Goswami S, Kodela R, Saavedra JE, Keefer LK, Kashfi K. JS-K, a nitric oxide-releasing prodrug, modulates β-catenin/TCF signaling in leukemic Jurkat cells: evidence of an S-nitrosylated mechanism. Biochem Pharmacol 2010, 80:1641-1649. 10.1016/j.bcp.2010.08.011, 20797387.
45. Wang P, Henning SM, Heber D. Limitations of MTT and MTS-based assays for measurement of antiproliferative activity of green tea polyphenols. PLoS One 2010, 5:e10202. 10.1371/journal.pone.0010202, 2855713, 20419137.
46. Tiedge M, Lortz S, Munday R, Lenzen S. Protection against the co-operative toxicity of nitric oxide and oxygen free radicals by overexpression of antioxidant enzymes in bioengineered insulin-producing RINm5F cells. Diabetologia 1999, 42:849-855. 10.1007/s001250051237, 10440128.
47. Royle JS, Ross JA, Ansell I, Bollina P, Tulloch DN, Habib FK. Nitric oxide donating nonsteroidal anti-inflammatory drugs induce apoptosis in human prostate cancer cell systems and human prostatic stroma via caspase-3. J Urol 2004, 172:338-344. 10.1097/01.ju.0000132367.02834.41, 15201807.
48. Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, Viale A, Kim K, Sawyers CL. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci USA 2010, 107:16759-16765. 10.1073/pnas.1012443107, 2947883, 20823238.
49. Spindler K-D, Laschak M, Cronauer MV. Nitric oxide - a tool to block nuclear receptors. Nuclear Receptors 2011, 87-102. New York: Nova Science Publishers Inc, Bates MK, Kerr RM.
50. Garbán HJ, Márquez-Garbán DC, Pietras RJ, Ignarro LJ. Rapid nitric oxide-mediated S-nitrosylation of estrogen receptor: regulation of estrogen-dependent gene transcription. Proc Natl Acad Sci USA 2005, 102:2632-2636. 10.1073/pnas.0409854102, 548976, 15699347.
51. Siemens DR, Heaton JP, Adams MA, Kawakami J, Graham CH. Phase II study of nitric oxide donor for men with increasing prostate-specific antigen level after surgery or radiotherapy for prostate cancer. Urology 2009, 74:878-883. 10.1016/j.urology.2009.03.004, 19476985.
52. Bico P, Chen CY, Jones M, Erhardt J, Dirr H. Class pi glutathione S-transferase: Meisenheimer complex formation. Biochem Mol Biol Int 1994, 33:887-892.
53. Cronauer MV, Braun S, Tremmel C, Kröncke KD, Spindler-Barth M. Nuclear localization and DNA binding of ecdysone receptor and ultraspiracle. Arch Insect Biochem Physiol 2007, 65:125-133. 10.1002/arch.20184, 17570142.